Inhibikase swaps 18,030,000 shares for RA Capital pre-funded warrant in unregistered offering
IKT•Unregistered issuance basis
The unregistered issuance relied on the Securities Act Section 3(a)(9) exemption.
Exchange agreement with RA Capital
Inhibikase Therapeutics entered an exchange agreement on July 29, 2026 with RA Capital Healthcare Fund.
RA Capital exchanged 18,030,000 common shares for a pre-funded warrant to buy 18,030,000 common shares.
Warrant terms and ownership limits
The pre-funded warrant is immediately exercisable at $0.001 per share with no expiration date.
Exercise is capped by a 9.99% beneficial ownership blocker, adjustable on 61 days’ notice up to 19.99%.
